Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.74 |
| ▸ | MAPT | P10636 | 2/20 | 0.74 |
| ▸ | MEN1 | O00255 | 2/20 | 0.74 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.74 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.74 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.74 |
| ▸ | SQLE | Q14534 | 6/20 | 0.52 |
| ▸ | ICMT | O60725 | 1/20 | 0.47 |
| ▸ | BTN3A1 | O00481 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15361567 | 1.00 | KMT2A (0.74) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL31312707 | 1.00 | KMT2A (0.74) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL7116219 | 1.00 | KMT2A (0.74) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL30170465 | 1.00 | KMT2A (0.74) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL10323892 | 1.00 | KMT2A (0.74) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL3084544 | 1.00 | KMT2A (0.74) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL900303 | 1.00 | KMT2A (0.74) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL900304 | 1.00 | KMT2A (0.74) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL11042453 | 1.00 | KMT2A (0.74) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL17953126 | 1.00 | KMT2A (0.74) | KMT2AMAPTMEN1CYP3A4ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240218111-A1 | EPOXY RESIN WITH IMPROVED WATER RESISTANCE AND COMPOSITION COMPRISING SAME | SAMYANG CORPORATION (KR) | 2024-07-04 | — | — | US | disclosed |
| US-8227645-B2 | Cyclisation process of forming a multiple ring compound | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2012-07-24 | — | — | US | disclosed |
| US-20100228058-A1 | CYCLISATION PROCESS OF FORMING A MULTIPLE RING COMPOUND | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2010-09-09 | — | — | US | disclosed |
| US-7629400-B2 | Image making medium | HYMAN SYDNEY | 2009-12-08 | — | — | US | disclosed |
| US-20030035917-A1 | Image making medium | HYMAN SYDNEY (US) | 2003-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100228058-A1 | CYCLISATION PROCESS OF FORMING A MULTIPLE RING COMPOUND | DHPS, GGPS1, COASY | KMT2A 2281/4885MAPT 4010/4885MEN1 458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.